argenx Reports Positive Phase 3 ADAPT OCULUS Results for VYVGART in Ocular Myasthenia Gravis

Reuters02-26
argenx Reports Positive Phase 3 ADAPT OCULUS Results for VYVGART in Ocular Myasthenia Gravis

argenx SE announced positive topline results from the Phase 3 ADAPT OCULUS randomized, double-blind, placebo-controlled trial evaluating VYVGART (efgartigimod alfa and hyaluronidase-qvfc) administered subcutaneously in adults with ocular myasthenia gravis. The study met its primary endpoint, showing a statistically significant improvement versus placebo in the Myasthenia Impairment Index patient-reported ocular score at Week 4 (p=0.012). The company said the data will be presented at an upcoming medical meeting and plans to submit a supplemental Biologics License Application to the U.S. FDA to expand the product label to ocular myasthenia gravis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260030PRIMZONEFULLFEED1001166814) on February 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment